BEVIRIMAT
(MPC-4326, PA-456)

Myriad Halts Development of HIV Maturation Inhibitor Bevirimat
6/11/2010

Bevirimat (MPC-4326) Resistance Is Common among Treatment-naive and Protease inhibitor-experienced HIV Patients
12/11/09

Myriad Begins Phase 2b Study of HIV Maturation Inhibitor MPC-4326 (Bevirimat) in Genetically-Identified Responders
12/08/09

HIV Maturation Inhibitor Bevirimat Demonstrates Promising Safety and Efficacy in Patients with Responsive HIV Genotype
9/25/09

Newer Anti-HIV Drugs and How to Use Them: Part 2
6/26/09

Experimental HIV Maturation Inhibitor Bevirimat Demonstrates Good Antiviral Activity and Favorable Safety Profile
10/04/08

Panacos Announces Data from Phase 2b Trial of HIV Maturation Inhibitor Bevirimat (PA-457)
3/07/2008